Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Current Medical Research and Opinion|October 15, 2010
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational studyDenis Moro-Sibilot, Alain Vergnenegre, Egbert F Smit, et al.Current Medical Research and Opinion|June 16, 2012
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational studyAlain Vergnenegre, Egbert F Smit, Elisabeth Toy, et al.Clinical Lung Cancer|September 24, 2005
Multicenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902Herve LeCaer, Jean Yves Delhoume, Pascal Andre Thomas, et al.Expert Review of Anticancer Therapy|September 25, 2014
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapyStefan Walzer, Christos Chouaid, Johanna Lister, et al.Lung Cancer (Amsterdam, Netherlands)|September 28, 2021
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study)Jean-Bernard Auliac, Isabelle Monnet, Acya Bizieux, et al.Targeted Oncology|August 2, 2017
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)Jean-Bernard Auliac, Isabelle Monnet, Catherine Dubos-Arvis, et al.Translational Lung Cancer Research|March 26, 2015
ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutationNiki Karachaliou, Ana Gimenez-Capitan, Ana Drozdowskyj, et al.Oncotarget|November 8, 2013
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapyLaura Bonanno, Carlota Costa, Margarita Majem, et al.Cancer Medicine|November 21, 2019
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04)Alain Vergnenegre, Margaux Geier, Florian Guisier, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2010
Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 studyRenaud Descourt, Alain Vergnenegre, Fabrice Barlesi, et al.Pageof 6